Neoadjuvant Chemotherapy plus Interval Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy (NIHIPEC) in the Treatment of Advanced Ovarian Cancer: A Multicentric Propensity Score Study
Ver/ Abrir
Impacto
Scholar |
Otros documentos de la autoría: Llueca, Antoni; Ibáñez Gual, Maria Victoria; CASCALES SANCHEZ, PEDRO; Gil-Moreno, Antonio; Bebia, Vicente; Ponce, Jordi; Fernandez, Sergi; Arjona-Sanchez, Alvaro; Muruzabal Torquemada, Juan Carlos; Veiga-Canuto, Nadia; Díaz-Feijoo, Berta; Celada Castro, Cristina; Gilabert-Estellés, Juan; AGHABABYAN, KRISTINA; Lacueva, Francisco Javier; Calero, Alicia; Segura-Sampedro, Juan José; Maiocchi, Karina; Llorca Cardeñosa, Sara; Villarín, Álvaro; CLIMENT MARTÍ, MARIA TERESA; Delgado Barriga, Katty; Serra Rubert, Anna; GOMEZ QUILES, LUIS; Llueca, Maria; Spain GOG and GECOP Working Group
Metadatos
Mostrar el registro completo del ítemcomunitat-uji-handle:10234/9
comunitat-uji-handle2:10234/36080
comunitat-uji-handle3:10234/36082
comunitat-uji-handle4:
INVESTIGACIONMetadatos
Título
Neoadjuvant Chemotherapy plus Interval Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy (NIHIPEC) in the Treatment of Advanced Ovarian Cancer: A Multicentric Propensity Score StudyAutoría
Fecha de publicación
2023-08-26Editor
MDPICita bibliográfica
Llueca, A.; Ibañez, M.V.; Cascales, P.; Gil-Moreno, A.; Bebia, V.; Ponce, J.; Fernandez, S.; Arjona-Sanchez, A.; Muruzabal, J.C.; Veiga, N.; et al. Neoadjuvant Chemotherapy plus Interval Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy (NIHIPEC) in the Treatment of Advanced Ovarian Cancer: A Multicentric Propensity Score Study. Cancers 2023, 15, 4271. https://doi.org/10.3390/cancers15174271Tipo de documento
info:eu-repo/semantics/articleVersión
info:eu-repo/semantics/publishedVersionPalabras clave / Materias
Resumen
Simple Summary Advanced ovarian cancer (Stages III-IV) continues to be one of the gynecological tumors with the highest mortality. Standard treatment consists of debulking surgery and subsequent adjuvant chemotherapy. ... [+]
Simple Summary Advanced ovarian cancer (Stages III-IV) continues to be one of the gynecological tumors with the highest mortality. Standard treatment consists of debulking surgery and subsequent adjuvant chemotherapy. Recently, some authors have postulated that the administration of hyperthermic chemotherapy during surgery could increase the survival of patients, especially in cases in which chemotherapy had already been administered before surgery to reduce tumor volume. Our study is important because it collects data from 11 tertiary hospitals in Spain, and the data are subjected to a statistical technique that reproduces the data that we would find in a prospective study but using retrospective data (propensity score matching). It also offers a current view of the status of ovarian cancer treatment in our country.Abstract Introduction: Epithelial ovarian cancer (EOC) is primarily confined to the peritoneal cavity. When primary complete surgery is not possible, neoadjuvant chemotherapy (NACT) is provided; however, the peritoneum-plasma barrier hinders the drug effect. The intraperitoneal administration of chemotherapy could eliminate residual microscopic peritoneal tumor cells and increase this effect by hyperthermia. Intraperitoneal hyperthermic chemotherapy (HIPEC) after interval cytoreductive surgery could improve outcomes in terms of disease-free survival (DFS) and overall survival (OS). Materials and Methods: A multicenter, retrospective observational study of advanced EOC patients who underwent interval cytoreductive surgery alone (CRSnoH) or interval cytoreductive surgery plus HIPEC (CRSH) was carried out in Spain between 07/2012 and 12/2021. A total of 515 patients were selected. Progression-free survival (PFS) and OS analyses were performed. The series of patients who underwent CRSH or CRSnoH was balanced regarding the risk factors using a statistical analysis technique called propensity score matching. Results: A total of 170 patients were included in each subgroup. The complete surgery rate was similar in both groups (79.4% vs. 84.7%). The median PFS times were 16 and 13 months in the CRSH and CRSnoH groups, respectively (Hazard ratio (HR) 0.74; 95% CI, 0.58-0.94; p = 0.031). The median OS times were 56 and 50 months in the CRSH and CRSnoH groups, respectively (HR, 0.88; 95% CI, 0.64-1.20; p = 0.44). There was no increase in complications in the CRSH group. Conclusion: The addition of HIPEC after interval cytoreductive surgery is safe and increases DFS in advanced EOC patients. [-]
Entidad financiadora
Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO)
Derechos de acceso
info:eu-repo/semantics/openAccess
Aparece en las colecciones
- MED_Articles [667]
Excepto si se señala otra cosa, la licencia del ítem se describe como: © 2023 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).